In 1950 Klopp and his colleagues, in their now classic paper, described the treatment of patients with localized cancer by the intra-arterial injection of nitrogen mustard (mustine hydrochloride; HN2). The advantage over systemic therapy of such regional administration into an appropriate artery was that an unprecedentedly high concentration of drug could be delivered to a relatively small volume of tissue in a total dose which would not seriously affect the rest of the patient. Klopp suggested that the ideal agent for regional chemotherapy would be absorbed or inactivated by the time it entered the veins, and the recent development of alkylating agents with extremely short half-lives partially fulfils his criteria. Klopp also proposed that, failing this ideal agent, the toxicity of a regionally administered drug might be reduced by supplying systemically an antagonist to any of that drug which spilled over via the veins into the general circulation. Alternatively the affected part could be isolated from the rest of the body, e.g. by a tourniquet, and its circulation containing the agent maintained by a pump-oxygenator.
We now have nearly three years' experience at Westminster Hospital of the use of cytotoxic agents by simple intra-arterial administration, that is by continuous slow drip infusion, or by intermittent single dose injection. In the first part of this period 50 patients were treated by continuous infusion of the antimetabolite methotrexate (4-amino-N'0-methyl-pteroyl glutamic acid). There followed a smaller series of 22 patients who received continuous infusions of vinblastine, a plant extract which in part acts as an antimetabolite. Twenty more patients with cerebral tumours were treated either by intracarotid injections of thioTEPA as the sole measure or by intra-carotid injections of vinblastine in conjunction with radiotherapy. A further 20 patients with advanced pelvic visceral cancer received intra-aortic injections of HN2. Most recently the epoxide, epodyl (triethyleneglycol diglycidyl ether; TEG) was given in fractionated doses to various regions in 32 patients. Finally a small, miscellaneous group of patients received cytotoxic agents other than those already mentioned. Sullivan et al. (1959) pointed out the need for continuous infusion with methotrexate since, unlike the quicker acting alkylating agents, this drug required to be in contact with the tissues for prolonged periods of time, i.e. days or weeks, in order to produce biological effects, and was ineffective after short exposures.
Continuous Infusion ofMethotrexate
Forty-three patients with head and neck cancer received continuous infusions of methotrexate: 27 were treated in the manner described by Sullivan et al., i.e. by infusion of ordinarily lethal doses in the region of 50 mg daily, covered by the specific antagonist, folinic acid (citrovorum factor; leucovorin), 24 mg daily given intramuscularly in four divided doses. The remaining 16 patients were given methotrexate in more conventional dosage, e.g. 3 mg daily, without folinic acid. In this latter group oral toxicity was generally more intense but the total duration of treatment was reduced by more severe bone marrow depression. Table 1 shows the immediate results of infusion of methotrexate with folinic acid cover. Some degree of objective regression accompanied by gratifying pain relief was the rule, but complete clinical disappearance of tumour occurred in 3 patients only. In 2 of these recurrence took place within three months, while the remaining patient remained free from disease till his death seven months later from an unrelated cause. The longest overall period of infusion in this group was one month and the highest total dose of methotrexate 812 mg. In any given course, administration of methotrexate would be interrupted on one or more occasions to allow recovery from local or systemic toxic effects, and the course was prolonged where technically possible until maximum regression or complete disappearance of tumour was achieved. Table 2 shows the results of infusion of methotrexate alone; the figures were similar to those in the former group but in no patient did remission last more than three months. Local toxicity from methotrexate took the form of a painful erythema of the mucosal surfaces, leading to shallow ulceration and finally a thick yellow film like an irradiation film. Leucopenia occurred frequently but recovered on discontinuing methotrexate in all but one patient who was in the group without folinic acid cover. This was the only death in the series due to the drug itself. Gastro-intestinal complications were not seen.
We also used continuous regional infusion of methotrexate on a few occasions for tumours of the liver, limbs, uterine cervix and lung.
Our experience with regionally infused methotrexate has been described in greater detail in previous publications , Westbury 1962 ).
Continuous Infusion of Vinblastine
Vinblastine was selected for trial intra-arterially because of favourable reports of its use systemically in a wide variety of tumours, and in order to make the best use of the then scarce supply of this agent. Twenty out of the 22 patients treated had head and neck tumours. One patient had melanomatous metastases in the liver which failed to respond; in another patient with a malignant melanoma of the chest wall, partial regression followed the combination of phenylalanine mustard (melphalan; PAM) and vinblastine. The results in the head and neck group are shown in Table 3 . Again, recurrence followed apparently complete regression after periods of two weeks to two months. Vinblastine produced a mucosal effect similar to that of methotrexate and in addition a skin reaction of an intensity seldom seen with the latter agentpainful erythema leading to temporary epilation of the beard and scalp. Vinblastine had the great advantage that a severe local tissue effect was usually produced short of serious depression of the white cell count. The usual dose was 2 mg daily and the maximum total amount infused was 79 mg over thirty-five days.
Patients with head and neck cancer formed the greater part of our experience with continuous infusion therapy. Four patients originally infused with methotrexate were subsequently given vinblastine and several patients were infused on two or even three separate occasions so that, in all, 69 infusions were carried out in 59 patients with head and neck tumours. The procedure was associated with considerable morbidity. Septicimia occurred in 11 patients, secondary htmorrhage in 2 patients and transient hemiplegia in 4. One other patient suffered permanent cerebral damage and there were five surgical deaths, in addition to that mentioned from methotrexate toxicity.
Intermittent Intra-aortic Injection ofHN2
for Pelvic Visceral Cancer HN2 was given regionally in intermittent doses of 20-30 mg on up to three occasions to 14 patients with advanced carcinoma of the cervix. The drug was delivered at the aortic bifurcation by percutaneous transfemoral catheterization and sphygmomanometer cuffs were inflated above arterial pressure on each thigh at the time of injection to spare the lower limbs. Palliation of symptoms lasting at least two months was achieved in 7 patients; objective remission occurred in 2 only. Three patients with advanced rectal carcinoma, and one each with leiomyosarcoma of the uterus, carcinoma of the vagina and carcinoma of the prostate showed no response.
Regional Chemotherapy ofCerebral Tumours
The danger of embolism of clot and air associated with an indwelling catheter, and especially with continuous infusions, led us to adopt repeated carotid puncture for regional chemotherapy of the brain. Davis & Shumway (1961) reported encouraging results with cerebral tumours treated by thioTEPA injected into the internal carotid artery, and we have treated 11 patients in this way, 8 of whom had primary cerebral tumours and 3 metastases. The maximum total dose ofthioTEPA was 315 mg given in four injections over eight weeks. Temporary objective remission occurred in 7 patients, but all are now dead. More recently 9 patients were given vinblastine as a radiopotentiator by intermittent intra-carotid injection, but it is too early to assess the value, if any, of this modification.
Intermittent Injection ofEpodyl Epodyl was administered by intermittent intraarterial injection in 32 patients; the distribution of their disease is shown in Table 4 . The agent was injected into the appropriate artery via an indwelling catheter fitted to a Gordh-Forrest adaptor and filled with heparin between injections. One patient retains his catheter in the subclavian artery, still patent, more than four months after its introduction, and has been an out-patient for the last two months. There were 11 patients with head and neck tumours; the results of treatment are indicated in Table 5 . Epodyl was given in an initial dose of 1-5 ml rising to 2-5 ml three times weekly. The maximum total dose injected into one external carotid artery was 25 5 ml over nineteen days, but one patient treated bilaterally was given 16-5 ml into each external carotid over twenty-six days. The last patient's white cell count fell to 3,100 but leucopenia was not seen in the other patients in this group. Local effects on the normal tissues were severe: mucositis was indistinguishable from that following methotrexate infusion; skin erythema was produced frequently and was followed by pigmentation and atrophy. After the third or fourth injection most patients complained of pain in the face during and for some hours following each dose.
Eight patients with malignant melanoma of the lower limb received treatment with epodyl. In one the agent was given prior to block dissection of the groin; in a second patient with multiple skin deposits no effects on the tumour was observed. The remaining 6, all with cutaneous lesions, responded partially, and some nodules disappeared completely. One patient showed marked regression of an undifferentiated soft tissue sarcoma at the knee, and another with mycosis fungoides complete disappearance of lesions in both lower limbs. A child with recurrent round cell sarcoma of the humerus failed to respond. Treatment in the lower limbs was again conducted by means of an indwelling plastic catheter kept patent with heparin. These patients were able to move about freely, and two were treated for a short time as out-patients. After a test dose of 1-5 ml, the volume of injection was increased to a maximum of 5 ml three times weekly. The largest single dose was 7 5 ml and the maximum total dose 49 ml over twenty-one days. Neurotoxicitymotor weakness and sensory lossoccurred in 4 patients, and was preceded by parnsthesie following injection; this symptom calls for great caution in proceeding with treatment. Erythema and skin blistering was sometimes produced with the larger doses. Significant bone marrow depression was seen in two patients, in one of whom the white cell count feU to 800 per c.mm after 45 5 ml of epodyl injected over twenty-one days, but recovered spontaneously.
Seven patients with carcinoma of the uterine cervix were treated by intra-aortic injections of epodyl, rising to 5 0 ml three times weekly, to a maximum dose of 28 ml over twenty-one days. Subjective improvement was noted in three instances, and definite regression of the pelvic mass in one.
No response followed treatment in one patient with malignant melanoma of the chest wall, and in another with melanomatous liver metastases. A further patient with metastatic melanoma in axillary lymph nodes received subclavian injections of epodyl prior to block dissection.
In the entire series of patients treated by intermittent injection of cytotoxic agents there was one death due to therapy in a 75-year-old man who developed deep vein thrombosis in the treated leg complicated by massive pulmonary embolism.
Another patient with carcinoma of the cervix, treated via an indwelling arterial catheter, developed infection at the femoral puncture site and septic emboli to the feet; this resolved on removing the catheter and displaying an appropriate antibiotic.
We are not yet in a position to compare the effectiveness of continuous antimetabolite infusion with intermittent injection of acutely cytotoxic agents, though Klopp et al. (1961) drew conclusions in favour of the latter from a much smaller group of patients. It is, however, obvious that the intermittent technique is simpler, safer and far less burdensome to the patient.
Discussion
In reviewing this series of approximately 150 patients, it is apparent that regression has been produced in so-called solid tumours which was never achieved by systemic chemotherapy. Unfortunately, while some degree of tumour response in the treated territory followed in the majority of cases, this was usually incomplete and seldom long lasting. Furthermore the area of effectiveness of regional treatment was strictly limited by the vascular anatomy as shown by the failure of tumour regression in areas outside the particular capillary bed which could be outlined by intra-arterial dye injection.
We thought that these disappointing results might have been influenced by our selection of cases; most patients had hopelessly advanced disease and had usually been subjected to previous surgery and/or irradiation. Indeed, a review of the literature indicates similar results in roughly comparable series (Sullivan 1962 , Hall et al. 1962 .
These considerations lead us to the view that, at present, regional chemotherapy by intraarterial infusion and injection, though possibly a valuable addition to surgery and irradiation in the early case, and a useful palliative measure for the otherwise hopeless case, in no way replaces conventional methods of treatment of localized cancer.
Summary
(1) The results of continuous intra-arterial infusion and intermittent intra-arterial injection of cytotoxic agents in 150 patients are described.
(2) Regional chemotherapy by these techniques has frequently produced tumour regression, but this has seldom been long lasting.
Extracorporeal Arterial Perfusion'
by Professor W T Irvine MD chM (Surgical Unit, St Mary's Hospital, London) In order to avoid the severe local reactions or vascular thrombosis which followed intra-arterial injections of chemotherapeutic agents, such as those described by Cook (1959) and by Ryan et al. (1958) , Creech et al. (1958) introduced techniques whereby the tumour-bearing area of the body was isolated from the systemic circulation, its blood flow being maintained by a pump-oxygenating machine.
By reducing the amount of agent reaching the marrow and gastro-intestinal tract much higher levels could be administered to the tumourbearing area. In addition, when the drug had been mixed in the pump before reaching the arteries, a much higher dosage was possible than with simple intra-arterial injection. Not only is greater total dosage of the drug permissible by this means; but, because the perfused volume is in the order of 20 % of the total blood volume, the concentration of the chemotherapeutic agent in the tumour area is fifteen to twenty times greater than that obtainable by systemic therapy (Henschke & Cole 1961) . Lastly, using the pump-oxygenator it was possible to raise the arterial oxygen tension in the region perfused more than fourfold; because these agents were thought to act in a similar way to X-rays this might increase the vulnerability of the malignant cells (Churchill-Davidson et al. 1957 , Gray 1957 , and experimental evidence was produced that raising the oxygen tension did enhance the effect of these drugs (Krementz et al. 1960 ).
This technique was later extended to patients with widespread malignant deposits, and totalbody perfusion was carried out after removing some of the patient's own marrow for reinfusion later, when the action of the drugs had ceased. By the end of 1959 Creech and his colleagues reported 145 cases which had undergone regional or total-body perfusion, with some regression in about half of them (Creech et al. 1959a ). Others using similar regional techniques have reported the results of treating tumours of the pelvis (Austen et al. 1959), brain (Woodhall et al. 1959 ), head and neck (Woodhall et al. 1960 ), lungs (Pierpont 1960 , and indeed the whole abdominal viscera and liver (Shingleton et al. 1960 ).
As regional chemotherapy with an extracorporeal circuit developed, the local factors in 'This paper is a revised version of that by Irvine et al. (1962) and Ls printed here by permission of the Editor of the Lancet
